Company Overview
Company Type: Private Company
Website: www.biotrial.com
Number of Employees: 4
Year Founded: 1989
Total Amount Raised (CAD mm)†: 16.46
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Biotrial S.A.S. provides drug evaluation and pharmacology research services. It offers services in the areas of non-clinical pharmacology, early development and translational medicine, patient studies, oncology trials, bio analysis, core lab, biometrics, regulatory affairs and pharma-covigilance. Biotrial S.A.S. was founded in 1989 and is based in Rennes, France. It has strategic locations in Rennes, Nantes, and Mulhouse, France; London, United Kingdom; Newark, New Jersey; Brussels, Belgium; and Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 23.4
Operating Income
 3.5
Total Assets
 24.7
Gross Profit
 23.1
EBITDA
 3.6
Total Debt
 1.4
Net Income
 3.3
Estimated Number of Employees
 4
Net Debt
 (15.4)
Private Co. Financial Data  as of Dec-31-2010. * Hover over data point numbers for date and source.

Key Professionals
Name
Title
Gandon, Jean-Marc
Founder, Chief Executive Officer and President 
Patat, Alain
Chief Medical & Scientific Officer and Head of Regulatory Affairs
Verhaaren, Frans 
Business Development Director
la Rochelle, Christophe Drieu
Head of Non-Clinical Pharmacology Department
Mancini, Michael
President of Biotrial Bioanalytical Services, Inc


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
7-9 rue Jean-Louis Bertrand | Rennes, Brittany | 35000 | France
Phone: 33 2 99 59 91 91   Fax: 33 2 99 59 91 97

Prior Investors
Unexo, SAS


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Warnex Inc., Bioanalytical Services Division
As of December 10, 2012, Bioanalytical Services Division from Warnex Inc. was acquired by Biotrial Research S.A.S. Warnex Inc., Bioanalytical Services Division provides bioanalytical services to innovator, generic pharmaceutical, and biotechnology companies.

United States and Canada
Biotechnology
-
-
-
Biotrial
Commercial Physical Research

Europe
Research and Consulting Services
4.00
-
-
Biotrial Paris
Biotrial Paris operates as a biotechnology company. It provides research and experimental development on biotechnology. The company is based in France.

Europe
Biotechnology
6.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-21-2019
Jun-21-2019
Private Placement
Target
Biotrial S.A.S.


12.45
Oct-25-2012
Dec-10-2012
Merger/Acquisition
Buyer
Warnex Inc., Bioanalytical Services Division
Biotrial S.A.S.
Warnex Inc.
5.43
Apr-5-2004
Apr-5-2004
Private Placement
Target
Biotrial S.A.S.
Unexo, SAS

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-21-2019
Private Placements
Biotrial S.A.S. announced that it has received €11 million in funding
Dec-10-2012
M&A Transaction Closings
Biotrial Research S.A.S. completed the acquisition of bioanalytical services division from Warnex Inc. (TSXV: WNX).
Oct-25-2012
M&A Transaction Announcements
Biotrial Research S.A.S. entered into a binding agreement to acquire bioanalytical services division from Warnex Inc. (TSXV: WNX) for CAD 6 million.
May-03-2010
Company Conference Presentations
Biotrial S.A. Presents at 2010 BIO International Convention, May-03-2010
Apr-05-2004
Private Placements
Announced Private Placement Transaction - Target: Biotrial S.A.; Investor(s): Uni Expansion Ouest

M&A Advisors
Aust Legal Inc.


Advisors
M&A Advisors
Aust Legal Inc.


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Gandon, Jean-Marc
Founder, Chief Executive Officer and President 
33 2 99 59 91 91
33 2 99 59 91 97
jean-marc.gandon@biotrial.com
Patat, Alain
Chief Medical & Scientific Officer and Head of Regulatory Affairs
33 2 99 59 91 91
33 2 99 59 91 97
-
Verhaaren, Frans 
Business Development Director
33 2 99 59 91 91
33 2 99 59 91 97

la Rochelle, Christophe Drieu
Head of Non-Clinical Pharmacology Department
33 2 99 59 91 91
33 2 99 59 91 97
-
Mancini, Michael
President of Biotrial Bioanalytical Services, Inc
33 2 99 59 91 91
33 2 99 59 91 97
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
